GC
KRYS icon

Guggenheim Capital’s Krystal Biotech KRYS Stock Holding History

Guggenheim Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
6,720
+3,202
+91% +$957K 0.02% 661
2026
Q1 		$909K Sell
3,518
-3,734
-51% -$994K 0.01% 1021
2025
Q4 		$1.79M Buy
7,252
+3,200
+79% +$674K 0.01% 701
2025
Q3 		$715K Sell
4,052
-2,010
-33% -$301K 0.01% 1041
2025
Q2 		$833K Buy
6,062
+1,909
+46% +$280K 0.01% 949
2025
Q1 		$749K Sell
4,153
-709
-15% -$119K 0.01% 1012
2024
Q4 		$762K Buy
4,862
+927
+24% +$164K 0.01% 1035
2024
Q3 		$716K Sell
3,935
-774
-16% -$149K 0.01% 1253
2024
Q2 		$865K Buy
4,709
+373
+9% +$62.6K 0.01% 1192
2024
Q1 		$772K Sell
4,336
-1,103
-20% -$153K 0.01% 1300
2023
Q4 		$675K Buy
+5,439
New +$603K 0.01% 1330

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Guggenheim Capital's KRYS Position: Q2 2026 in Review

Guggenheim Capital increased its Krystal Biotech (KRYS) stake by 91% in Q2 2026, buying an estimated $957K and bringing the position to 6,720 shares worth $2.5M. The position accounts for 0.02% of the portfolio, ranked #661.

Guggenheim Capital first reported a position in KRYS in Q4 2023 and has held it in 11 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Guggenheim Capital held 6,720 shares of Krystal Biotech worth $2.5M as of Q2 2026.
  • Guggenheim Capital bought 3,202 Krystal Biotech shares in Q2 2026, an estimated $957K.
  • Krystal Biotech made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #661 holding.
  • Guggenheim Capital first reported a position in Krystal Biotech in Q4 2023 and has held it in 11 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.